Cargando…
Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell proliferative disorder associated with risk of progression to symptomatic multiple myeloma (MM) or amyloidosis. In comparison to monoclonal gammopathy of undetermined significance (MGUS), SMM has a much higher risk of progression to MM...
Autores principales: | Blum, Agnieszka, Bazou, Despina, O’Gorman, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467346/ https://www.ncbi.nlm.nih.gov/pubmed/31360091 http://dx.doi.org/10.2147/BLCTT.S136447 |
Ejemplares similares
-
Marizomib: A novel therapeutic approach for the treatment of central nervous system myeloma
por: Bazou, Despina, et al.
Publicado: (2020) -
Smoldering multiple myeloma current treatment algorithms
por: Rajkumar, S. Vincent, et al.
Publicado: (2022) -
Using Proteomics Data to Identify Personalized Treatments in Multiple Myeloma: A Machine Learning Approach
por: Katsenou, Angeliki, et al.
Publicado: (2023) -
Smoldering Multiple Myeloma
por: Gao, Minjie, et al.
Publicado: (2015) -
Current Methods of Post-Translational Modification Analysis and Their Applications in Blood Cancers
por: Dunphy, Katie, et al.
Publicado: (2021)